| 書目名稱 | Perspectives in Antiinfective Therapy | | 副標(biāo)題 | Washington D.C., Aug | | 編輯 | George Gee Jackson,H. D. Schlumberger,H.-J. Zeiler | | 視頻video | http://file.papertrans.cn/745/744699/744699.mp4 | | 叢書名稱 | Bayer AG Centenary Symposium | | 圖書封面 |  | | 描述 | Pharmaceutical research has a long-standing tradition at Bayer since the establish- ment of a Pharmaceutical Department 25 years after the foundation of the Farben- fabriken of Friedrich Bayer & Co. in the city of Elberfeld, Germany. In 1888, one of the first antipyretic drugs, phenacetin, was synthesized. A milestone was marked by the discovery and launch of Aspirin TM in 1899, the most widely used and appreciated drug since then. The success of Bayer 205 (GermaninTM) in the treatment of sleeping sickness led not only to the worldwide recognition of Bayer as a pharmaceutical company but also to intense research into antiinfective therapy. The antimalarial drugs Atebrin TM, Plasmochin TM and Resochin TM were the first of a whole series of significant contribu- tions and even breakthroughs in the therapy of infections. The advances and the success of antibacterial therapy were heralded by the discovery of the antibacterial activity of the sulfonamides by Domagk, Klarer and Mietsch. The first drug of this class of compounds, Prontosil?, opened the new era of therapeutic control of bacterial infections. In 1939, Domagk received the Nobel Prize for Medicine for this breakthrough. A fur | | 出版日期 | Conference proceedings 1989Latest edition | | 關(guān)鍵詞 | AIDS; Malaria; antibiotics; bacteria; chemotherapy; drug; immunotherapy; infection; infections; infectious di | | 版次 | 1 | | doi | https://doi.org/10.1007/978-3-642-46666-3 | | isbn_softcover | 978-3-540-50964-6 | | isbn_ebook | 978-3-642-46666-3Series ISSN 1431-116X | | issn_series | 1431-116X | | copyright | Springer-Verlag Berlin Heidelberg 1989 |
The information of publication is updating
|
|
|Archiver|手機(jī)版|小黑屋|
派博傳思國際
( 京公網(wǎng)安備110108008328)
GMT+8, 2025-10-17 00:50
發(fā)表于 2025-3-21 16:33:55
